Cue Biopharma/$CUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Ticker
$CUE
Sector
Primary listing
Employees
29
Headquarters
Website
Cue Biopharma Metrics
BasicAdvanced
$113m
-
-$5.22
2.55
-
Price and volume
Market cap
$113m
Beta
2.55
52-week high
$45.50
52-week low
$10.76
Average daily volume
154k
Financial strength
Current ratio
3.571
Quick ratio
3.341
Long term debt to equity
8.691
Total debt to equity
15.92
Interest coverage (TTM)
-84.06%
Profitability
EBITDA (TTM)
-18.162
Gross margin (TTM)
-2.63%
Net profit margin (TTM)
-59.65%
Operating margin (TTM)
-59.84%
Effective tax rate (TTM)
-2.63%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
-46.08%
Return on equity (TTM)
-138.52%
Valuation
Price to revenue (TTM)
3.068
Price to book
4.04
Price to tangible book (TTM)
4.04
Price to free cash flow (TTM)
-4.081
Free cash flow yield (TTM)
-24.51%
Free cash flow per share (TTM)
-6.577
Growth
Revenue change (TTM)
309.60%
Earnings per share change (TTM)
-73.20%
3-year revenue growth (CAGR)
323.15%
3-year earnings per share growth (CAGR)
-49.39%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.